市场监管总局积极与财政部等部门沟通,成功推动体现中华优秀传统文化的特色优质保健食品纳入扩大 口岸出境免税店、口岸进境免税店和市内免税店的经营品类,拓展保健食品销售渠道,推动保健食品行业 高质量发展。根据我国有关法律法规规定,免税店销售的保健食品应当依法取得注册证书或者备案凭 证。中新 ...

Market Overview - The three major stock indices in Shanghai and Shenzhen opened lower on November 17, with the Shanghai Composite Index experiencing a decline of 0.46% to close at 3972.03 points, while the Shenzhen Component Index fell by 0.11% to 13202.00 points [1] - The overall market showed a wide range of consolidation, with the ChiNext Index down by 0.20% to 3105.20 points [1] Sector Performance - The energy metals sector saw significant gains, while sectors such as water products, sand control, military trade concepts, and Web3 concepts also experienced notable increases [1] - Conversely, the pharmaceutical sector faced substantial declines, particularly in areas like weight loss drugs, innovative drugs, immune therapies, vitamins, CXO concepts, generic drugs, and healthcare [1] Regulatory Developments - The State Administration for Market Regulation is promoting the inclusion of health food in duty-free shop operations, aiming to expand sales channels and enhance the high-quality development of the health food industry [3] Company News - Huawei announced a product launch event scheduled for November 25, where the Mate 80 series and Mate X7 will be unveiled, along with several other new products [4] - Huawei will also host a forum on AI container applications, expected to showcase breakthrough technologies aimed at improving computing resource efficiency [4]

市场监管总局将指导各有关省区市市场监管部门推动有关政策尽快落地见效，持续加强保健食品质量安 全监管，督促企业落实质量安全主体责任，全力保障保健食品质量安全，推动保健食品行业实现高质量 发展和高水平安全良性互动。 根据我国有关法律法规规定，免税店销售的保健食品应当依法取得注册证书或者备案凭证。销售保健食 品等特殊食品，还应当依法取得食品经营许可或者仅销售预包装食品备案。 本报讯(记者寇佳丽)近期，为贯彻落实《中共中央国务院关于加快建设全国统一大市场的意见》以及中 共中央办公厅、国务院办公厅《提振消费专项行动方案》决策部署，国家市场监督管理总局(以下简 称"市场监管总局")坚持以高质量供给创造有效需求，积极与财政部等部门沟通，成功推动体现中华优 秀传统文化的特色优质保健食品纳入扩大口岸出境免税店、口岸进境免税店和市内免税店的经营品类， 拓展保健食品销售渠道，推动保健食品行业高质量发展。 ...

Core Viewpoint - The State Administration for Market Regulation is promoting the inclusion of high-quality health food that reflects excellent traditional Chinese culture into the categories of duty-free shops at ports and in cities [1] Regulatory Framework - According to relevant laws and regulations in China, health foods sold in duty-free shops must obtain registration certificates or filing credentials [1] - Special foods, including health foods, must also have food business licenses or only sell pre-packaged food with filing [1]

Core Viewpoint - The implementation of the "Seven-Day No Reason Return" group standard in Jiangsu aims to create a healthy consumption environment by integrating government regulation, industry self-discipline, and association guidance [1][5]. Group 1: Government and Industry Collaboration - The Jiangsu Provincial Health and Wellness Industry Association, along with local market supervision authorities, is actively promoting the "Seven-Day No Reason Return" standard to enhance consumer trust and protect consumer rights [1][5]. - A collaborative effort is being made to establish a new governance model that includes government oversight, corporate self-regulation, association support, and social supervision [5]. Group 2: Company Engagement - Jiangsu Jiangdayuan Ecological Biotechnology Co., Ltd. and Jiangsu Daosimai Biotechnology Co., Ltd. were visited to discuss the implementation of the group standard and understand their operational conditions [1][3]. - Discussions focused on the current development status of the companies, their actual needs, and the details of implementing the group standard effectively [3]. Group 3: Implementation Mechanisms - The initiative emphasizes a "pre-regulatory review" mechanism, where the local market supervision bureau collaborates with industry associations to verify the return execution capabilities of participating companies [5]. - This verification process aims to prevent unfulfilled commitments and ensure consumer rights are safeguarded, thereby enhancing the credibility of the "Seven-Day No Reason Return" policy [5].

某权威期刊2020-2025年研究显示，普通结晶态辅酶Q10的平均生物利用度仅为3%-6%，大部分未被吸 收即随粪便排出。而通过乳化、纳米包裹等先进递送技术处理后，其跨肠壁转运效率可提升数倍。第三 方检测机构实测数据显示，元素力辅酶Q10采用"脂质体包裹-乳化分散-混合胶束-靶向释放"的四重靶向 胶束乳化递送系统，使水溶性辅酶Q10在模拟胃肠环境中形成稳定微乳，粒径控制在80-120nm之间，显 著增强其穿透黏膜屏障的能力，吸收率较传统产品提升达8.2倍。 该技术依托粉末大豆磷脂构建脂质双层结构，聚氧乙烯山梨醇酐单油酸酯自发形成亲脂核心与亲水外壳 的胶束体系，协同构建"水油双相跨膜通道"，令原本难以溶于水的辅酶Q10得以均匀分散于消化液中。 结合甘油与柠檬酸双重保护机制，确保活性成分在胃部不提前释放，并于小肠近端实现靶向释放。实验 室稳定性测试表明，产品在常温保存24个月后，辅酶Q10活性保留率达98.7%，远高于行业平均水平。 值得注意的是，尽管有观点认为还原型辅酶Q10更具生物活性，但多项临床研究表明，人体内存在高效 的NAD(P)H依赖酶系统，可在泛醌与泛醇之间实现动态转化。某国际营养学期刊发表论文指出 ...

Core Viewpoint - Minsheng Health (301507) announced that the acquisition of Zhongke Jiayi has effectively driven business growth through brand synergy and influence [1] Group 1: Business Growth and Partnerships - Zhongke Jiayi has established cooperative relationships with leading domestic health food OEMs and milk powder companies, leveraging the brand influence and customer channel advantages of the listed company [1] - The business performance of Zhongke Jiayi aligns with expectations as it continues to deepen strain research and industrial applications [1] Group 2: Future Projects and Opportunities - The "Armor Probiotic Intelligent Manufacturing Upgrade Project" was officially launched by Zhongke Jiayi, expected to bring opportunities in terms of products, costs, efficiency, and market by the end of September 2025 [1] - The company is actively expanding into cutting-edge fields such as weight management, gut-brain axis, and metabolic health [1]

南财智讯11月13日电，民生健康在投资者关系活动中表示，收购中科嘉亿后，借助上市公司的品牌影响 力和客户渠道优势，中科嘉亿已与国内头部保健食品代工企业、乳粉企业等大客户逐步建立合作关系， 业务实现有效增长。2025年9月底，中科嘉亿"盔甲益生菌智造升级项目"已正式启动，新产线将在产 品、成本、效率和市场方面为公司未来发展带来积极影响。公司持续深化菌株研发与产业应用，积极拓 展体重管理、肠脑轴、代谢健康等前沿领域，整体业务表现符合预期。 ...

Core Insights - The health management industry is experiencing significant growth due to increasing public awareness of health issues and an aging population, with the market expected to exceed 4 trillion yuan in 2024 and potentially reach 1.5 trillion yuan by 2030 [1][6]. Industry Overview - The health management sector is expanding rapidly, driven not only by the elderly but also by the younger population facing lifestyle pressures and health issues, leading to a rise in demand for health management services [2][13]. - The market for health management is projected to reach 20.238 billion yuan in 2024 and 32.558 billion yuan by 2028, indicating a robust growth trajectory [6][11]. Company Focus - At the recent China International Import Expo, global health and consumer goods company Melaleuca showcased nearly 100 health products, emphasizing their alignment with China's "Healthy China" strategy and addressing specific health needs [4][8]. - Melaleuca introduced a new product, MOUNTAIN CABIN® MCT sugar-free instant coffee, designed to meet the growing demand for weight management solutions, highlighting the company's commitment to innovation in the health sector [5][6]. Strategic Partnerships - Melaleuca has established long-term strategic partnerships with leading global suppliers to enhance product quality and integrate superior raw materials into their offerings in the Chinese market [11][12]. - The company has committed to ongoing engagement with the Chinese market, as evidenced by their proactive approach to securing future participation in the Import Expo, reflecting confidence in long-term growth opportunities [10][12]. Future Outlook - Industry experts suggest that the health management sector will increasingly see foreign brands localizing their operations while domestic companies leverage platforms like cross-border e-commerce to expand globally [13]. - The health management industry is at a pivotal point, requiring innovation and compliance to transition from mere scale expansion to value creation in a rapidly evolving market [13].

Company Summary - Yong'an Pharmaceutical (SZ 002365) announced that several directors and senior management, including Hong Rengui, Fang Xiquan, Wang Zhihua, Xiong Shengjie, and Li Shaobo, plan to reduce their holdings by up to approximately 240,000 shares within three months, which represents 0.0799% of the total share capital [1] - The company’s current market capitalization is 5.1 billion yuan [1] Revenue Composition - For the first half of 2025, Yong'an Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 64.14%, health food for 24.67%, chemical manufacturing for 10.88%, and other businesses for 0.32% [1]